IDiyas

For the Inventor, By the Inventor

St. Louis, MO, United States of America

Donald J Rogier, Jr

USPTO Granted Patents = 31

Average Co-Inventor Count = 7.2

ph-index = 10

Forward Citations = 538(Granted Patents)


Location History:

  • St Louis, MO (US) (2004)
  • St. Louis, MO (US) (1995 - 2007)
  • Kalamazoo, MI (US) (2004 - 2008)

Company Filing History:

goldMedal20 out of 1,323 
 
G.d. Searle & Company
 patents
silverMedal5 out of 200 
 
Pharmacia Corporation
 patents
bronzeMedal3 out of 3,288 
 
Monsanto Company
 patents
4. 1 out of 2 
 
Mosanto Company
 patents
5. 1 out of 2 
 
Monsanto Company of St. Louis
 patents
6. 1 out of 832,680 
Other
 patents

Years Active: 1995-2008

Loading Chart...
31 patents (USPTO):Explore Patents
1. 7420061 - Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors (2008-09-02),
2. 7312333 - Retroviral protease inhibitors (2007-12-25),
3. 6951949 - Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation (2005-10-04),
4. 6822102 - Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of COX-2 mediated disorders (2004-11-23),
5. 6815460 - Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors (2004-11-09),
6. 6806288 - Substituted benzopyran derivatives for the treatment (2004-10-19),
7. 6716991 - Process for preparing a substituted pyrazolyl benzenesulfonamide for the treatment of inflammation (2004-04-06),
8. 6586603 - Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation (2003-07-01),
9. 6492411 - Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation (2002-12-10),
10. 6413960 - Substituted pyrazolyl benzenesulfonamides for the treatment of asthma (2002-07-02),
11. 6156781 - Substituted pyrazolyl benzenesulfonamides for the treatment of (2000-12-05),
12. 5948790 - Retroviral protease inhibitors (1999-09-07),
13. 5908852 - 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation (1999-06-01),
14. 5760068 - Substituted pyrazolyl benzenesulfonamides for the treatment of (1998-06-02),
15. 5756534 - Retroviral protease inhibitors (1998-05-26),

Title: Donald J Rogier, Jr: A Pioneer in Inventions

Introduction: Donald J Rogier, Jr, hailing from St. Louis, MO (US), is a distinguished inventor whose passion for innovation and relentless pursuit of excellence have positioned him as a true pioneer in the world of inventions. With an impressive portfolio of 30 patents, he continues to inspire others to push the boundaries of what is possible in the realm of inventiveness.

Latest Patents: Among Donald J Rogier, Jr's notable patents are the Process for preparing prodrugs of benzenesulfonamide-containing COX-2 inhibitors, which are valuable in combating inflammation and inflammation-related disorders. Additionally, his work on Retroviral protease inhibitors, specifically N-heterocyclic moiety containing hydroxyethylamine compounds, has proven effective as retroviral protease inhibitors, particularly in inhibiting HIV protease.

Career Highlights: Donald J Rogier, Jr has contributed his innovative prowess to renowned companies like G.D. Searle & Company and Pharmacia Corporation. His collaborations within these esteemed organizations have fueled groundbreaking advancements in the field of pharmaceuticals and biotechnology.

Collaborations: Throughout his career, Donald J Rogier, Jr has worked closely with esteemed colleagues such as John Jeffrey Talley and Thomas Dale Penning. These collaborations have been instrumental in driving forward cutting-edge research and development initiatives, further solidifying his reputation as a trailblazer in the industry.

Conclusion: In conclusion, Donald J Rogier, Jr stands as a testament to the power of passion, perseverance, and ingenuity in the world of inventions. His unwavering dedication to innovation continues to shape the landscape of inventiveness, inspiring others to dare greatly and strive for excellence in all their pursuits.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…